Focused On-demand Library for Grainyhead-like protein 3 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8TE85

UPID:

GRHL3_HUMAN

Alternative names:

Sister of mammalian grainyhead; Transcription factor CP2-like 4

Alternative UPACC:

Q8TE85; A2A297; B2RCL1; G3XAF0; Q5TH78; Q86Y06; Q8N407

Background:

Grainyhead-like protein 3 homolog, also known as Sister of mammalian grainyhead and Transcription factor CP2-like 4, plays pivotal roles in primary neurulation and the differentiation of stratified epithelia. It binds directly to DNA, acting as both an activator and repressor of target genes. This protein exhibits redundancy with GRHL2 in epidermal morphogenesis and wound repair, and is crucial for epidermal barrier formation and repair post-immune-mediated damage.

Therapeutic significance:

Grainyhead-like protein 3 homolog is implicated in Van der Woude syndrome 2, a developmental disorder characterized by lip and palate anomalies. Understanding its role could unveil novel therapeutic strategies for this and potentially other epithelial barrier-related conditions.